Conmed (CNMD) Misses Q4 EPS by 5c, offers guidance

Conmed (NYSE: CNMD) reported Q4 EPS of $1.06, $0.05 worse than the analyst estimate of $1.11. Revenue for the quarter came in at $327 million versus the consensus estimate of $332.22 million.

GUIDANCE:

Conmed sees FY2024 EPS of $4.30-$4.40, versus the consensus of $4.40. Conmed sees FY2024 revenue of $1.34-1.365 billion, versus the consensus of $1.357 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Amneal gets FDA approval for lanreotide injection, launches immediately
• UBS cuts KOSPI target by nearly 10% to reflect higher rates